Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors

NCT02975037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Healthy

Interventions

DRUG: Sildenafil
DRUG: Clarithromycin
DRUG: Itraconazole

Sponsor

Seoul National University Hospital